Key Facts

PIPS Key Facts
Active Substance
Active Substance:
  • Genetically detoxified Pertussis Toxin (PTgen) and Pertussis Filamentous Haemagglutinin (FHA)
Invented Name
  • Pertagen
  • Pertagen
  • Pertagen
  • Pertagen aPgen
PIP Number MHRA-100978-PIP01-23
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Suspension for injection
Therapeutic area
Therapeutic area:
  • Vaccines
Conditions / Indications
Conditions / Indications:
  • Prevention of Pertussis disease
Route(s) of administration
Route(s) of administration:
  • Intramuscular use
PIP applicant
Decision Type
Decision Type
W: decision granting a waiver in all age groups for the listed condition(s).
Compliance Check
Compliance Check
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

PIPS Decision Documents
Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Genetically detoxified Pertussis Toxin (PTgen) andPertussis Filamentous Haemagglutinin (FHA).pdf
Published Date 30/01/2024